Home / Resource Library / Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Results of a study investigating CAR T therapy axicabtagene ciloleucel as first line treatment for large B-cell lymphomas.